NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free VXRT Stock Alerts $0.75 -0.02 (-2.24%) (As of 04:30 PM ET) Add Compare Share Share Today's Range$0.71▼$0.8250-Day Range$0.76▼$1.4152-Week Range$0.53▼$1.59Volume1.55 million shsAverage Volume1.97 million shsMarket Capitalization$131.82 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vaxart alerts: Email Address Vaxart MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside296.6% Upside$3.00 Price TargetShort InterestBearish9.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.14 out of 5 starsMedical Sector767th out of 910 stocksBiological Products, Except Diagnostic Industry132nd out of 153 stocks 3.5 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.72% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Vaxart has recently increased by 10.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VXRT. Previous Next 2.6 News and Social Media Coverage News SentimentVaxart has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vaxart this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows6 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.45) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Vaxart Stock (NASDAQ:VXRT)Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Read More VXRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VXRT Stock News HeadlinesApril 18, 2024 | americanbankingnews.comVaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average of $0.88April 9, 2024 | investorplace.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?April 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 27, 2024 | globenewswire.comVaxart to Present at World Vaccine Congress Washington 2024 on April 3March 20, 2024 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 17, 2024 | finance.yahoo.comEstimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)March 15, 2024 | finance.yahoo.comVaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | investorplace.comVXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023April 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 14, 2024 | finance.yahoo.comVaxart Inc (VXRT) Reports Full Year 2023 Financial ResultsMarch 14, 2024 | globenewswire.comVaxart Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comVaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14March 6, 2024 | marketwatch.comVaxart Names Steven Lo President, Chief ExecutiveMarch 6, 2024 | globenewswire.comVaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorFebruary 20, 2024 | finance.yahoo.comVAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?February 5, 2024 | finance.yahoo.comVaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 ChallengeJanuary 16, 2024 | marketwatch.comVaxart CEO Resigns; Biotech Raises $10 Million in Stock SaleJanuary 16, 2024 | finance.yahoo.comVaxart, Inc. Announces Management ChangeJanuary 16, 2024 | finance.yahoo.comVaxart Announces $10.0 Million Registered Direct Offering with RA Capital ManagementDecember 21, 2023 | finance.yahoo.comVaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersNovember 7, 2023 | finance.yahoo.comHere's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash WiselyNovember 3, 2023 | finance.yahoo.comVaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | finance.yahoo.comVaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business UpdatesNovember 2, 2023 | finance.yahoo.comVaxart Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comVaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersOctober 26, 2023 | finance.yahoo.comVaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2September 21, 2023 | finance.yahoo.comVaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare ConferenceSee More Headlines Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/23/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees109Year Founded2004Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+302.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,460,000.00 Net Margins-1,117.56% Pretax Margin-1,114.03% Return on Equity-108.45% Return on Assets-73.31% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual Sales$7.38 million Price / Sales17.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.96Miscellaneous Outstanding Shares176,840,000Free Float171,533,000Market Cap$131.82 million OptionableOptionable Beta0.44 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Sean N. Tucker Ph.D. (Age 55)Senior VP & Chief Scientific Officer Comp: $481.52kDr. James F. Cummings M.D. (Age 57)Chief Medical Officer Comp: $526.96kMr. Steven Lo (Age 57)President, CEO & Director Mr. Phillip Eric Lee (Age 36)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Raymond D. Stapleton Jr. (Age 53)Ph.D., Chief Technology Officer Mr. Edward B. Berg (Age 59)Senior VP & General Counsel Ms. Shaily Jaini GargSenior Vice President of Clinical Development & Project ManagementDr. Rajesh Kapoor Ph.D.Senior Vice President of QualityMore ExecutivesKey CompetitorsINmune BioNASDAQ:INMB10X Capital Venture Acquisition Corp. IIINYSE:VCXBLENZ TherapeuticsNASDAQ:LENZMolecular PartnersNASDAQ:MOLNCellectisNASDAQ:CLLSView All CompetitorsInstitutional OwnershipPFG Investments LLCBought 29,450 shares on 4/22/2024Ownership: 0.017%Kingswood Wealth Advisors LLCBought 25,000 shares on 4/15/2024Ownership: 0.014%Private Portfolio Partners LLCSold 8,500 shares on 2/7/2024Ownership: 0.067%Simplex Trading LLCSold 200 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions VXRT Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxart stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VXRT shares. View VXRT analyst ratings or view top-rated stocks. What is Vaxart's stock price target for 2024? 2 brokerages have issued twelve-month target prices for Vaxart's stock. Their VXRT share price targets range from $2.00 to $4.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 296.6% from the stock's current price. View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts. How have VXRT shares performed in 2024? Vaxart's stock was trading at $0.5728 at the beginning of 2024. Since then, VXRT shares have increased by 32.1% and is now trading at $0.7565. View the best growth stocks for 2024 here. When is Vaxart's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VXRT earnings forecast. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) posted its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. The biotechnology company had revenue of $3.25 million for the quarter, compared to the consensus estimate of $0.45 million. Vaxart had a negative trailing twelve-month return on equity of 108.45% and a negative net margin of 1,117.56%. What ETF holds Vaxart's stock? Amplify Treatments, Testing and Advancements ETF holds 39,829 shares of VXRT stock, representing 0.33% of its portfolio. When did Vaxart's stock split? Vaxart's stock reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN). Who are Vaxart's major shareholders? Vaxart's stock is owned by many different retail and institutional investors. Top institutional shareholders include PFG Investments LLC (0.02%) and Kingswood Wealth Advisors LLC (0.01%). Insiders that own company stock include Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, W Mark Watson and Wouter Latour. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VXRT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest MetalsIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
